Collaboration to Advance Data Driven Precision Medicine


SOPHiA GENETICS SA (“SOPHiA GENETICS”), a pioneer in data-driven medicine, and Hitachi, Ltd. (TSE: 6501, “Hitachi”) announced a long-term collaboration agreement to bring clinical, genomic and real-world insights to healthcare providers, pharmaceutical and biopharmaceutical companies  globally for the benefit of patients. Under this agreement, the two companies will advance data-driven precision medicine through global commercial expansion and development of Hitachi’s digital healthcare solutions and the SOPHiA DDM™ Platform.


SOPHiA GENETICS and Hitachi have identified multiple areas for potential collaboration including secure personal genomics data management, deployment of data and insights for better healthcare decisions and acceleration of drug development in oncology and other disease areas. Initially, the collaboration will focus on leveraging the genomics, clinical data analytics and AI expertise of both companies to expand the commercialization of the SOPHiA DDM™ Platform and Hitachi’s digital healthcare solutions, like Hitachi’s molecular tumor board support service, in key geographies. Over the long term, the two companies will also collaborate on R&D related new product development which is expected to lead to new joint offerings.


Keiji Kojima, Executive Vice President and Executive Officer, and General Manager of Smart Life Business Management Division of Hitachi, Ltd said, “SOPHiA GENETICS is a leader in precision medicine. Hitachi is excited to start a long term partnership with SOPHiA GENETICS to co-create innovative solutions for improving Quality of Life of patients by leveraging both companies’ data analytics and AI technologies.”


“At SOPHiA GENETICS, we are committed to improving patient outcomes through data driven medicine and we are excited to collaborate with Hitachi, a global leader in real-world evidence and multimodal clinical decision support, who shares these values,” said Jurgi Camblong, CEO and Founder of SOPHiA GENETICS. “This partnership will enable us to broaden our commercial reach and support improved health outcomes for more patients.”


The SOPHiA DDM™ Platform is a cloud-based software-as-a-service analytics platform that uses AI and machine learning to generate actionable insights for clinicians and researchers from complex multimodal datasets. These insights enable healthcare institutions to benefit from shared knowledge and, ultimately, improve diagnosis, treatment and drug development to drive better clinical and scientific outcomes.


Hitachi has been offering high value-added services, such as genomics, a medical and care data management platform and new services utilizing AI and analytics. Hitachi will broaden its healthcare business by leveraging its strengths of in-vitro diagnostics systems, particle therapy treatment systems and digital technologies, to contribute to the improvement of people’s quality of life and the realization of a sustainable society.